Cytomegalic Inclusion Disease
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Cytomegalic Inclusion Disease

What is the definition of Cytomegalic Inclusion Disease?
Cytomegalic inclusion disease is an infection in newborns caused by the cytomegalovirus. When a pregnant woman has an active cytomegalovirus infection during pregnancy or breastfeeding, the virus can be passed to their babies. Cytomegaloviruses are also known as salivary gland viruses.
What are the symptoms of Cytomegalic Inclusion Disease?
Symptoms of cytomegalic inclusion disease in the newborn can range from no symptoms to severe symptoms affecting the central nervous system, liver, spleen, and possibly causing developmental disabilities. Other symptoms of severe cytomegalic inclusion disease in infants may include hemorrhagic anemia, low birth weight, fever, hepatitis, yellowing of the skin and whites of the eyes, rash, purple skin blotches, pneumonia, enlarged liver and/or spleen, decreased blood platelets, eye inflammation, abnormally small head, calcification of the ventricles of the brain, developmental motor defects, cognitive disabilities, spastic paralysis, blindness, deafness, and seizures.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Cytomegalic Inclusion Disease?
There is currently no cure for cytomegalic inclusion disease. Treatment for cytomegalic inclusion disease is focused on controlling symptoms. Treatments for cytomegalic inclusion disease include antiviral drugs, such as gancicolovir and foscarnet; azathioprine; prednisone; basiliximab; and miconazole.
Who are the top Cytomegalic Inclusion Disease Local Doctors?
Elite in Cytomegalic Inclusion Disease
Infectious Disease
Elite in Cytomegalic Inclusion Disease
Infectious Disease
Referral may be required

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville

10751 Falls Road, Falls Concourse STE 412, Falls Concourse STE 412, 
Lutherville, MD 
Languages Spoken:
English
Offers Telehealth

Dr. Robin Avery is an infectious disease physician who joined the Johns Hopkins faculty in 2012, with two decades of experience in transplant infectious disease. She is a past chair of the American Society of Transplantation (AST) Infectious Disease Community of Practice, was a co-editor of the first edition of the AST ID Guidelines, and serves on a Guidelines Committee for the Infectious Disease Society of America (IDSA) on immunizations in the immunocompromised host. She was the founding head of the Transplant Infectious Disease Section at the Cleveland Clinic and served as the founding director of the Cleveland Clinic Transplant ID Special Fellowship, authoring a curriculum that served as the basis for curricula later endorsed by the AST and IDSA. Her clinical and research interests include pre-transplant donor and recipient evaluation, and prevention and treatment of post-transplant infections, particularly transplant-associated viruses, viral load monitoring, novel therapies for CMV, hypogammaglobulinemia, immunizations, and strategies for safer living post-transplant. She has a strong interest in patient education and co-authored the script for a video designed to educate patients on decreasing post-transplant infection risks. Dr. Avery is rated as an Elite provider by MediFind in the treatment of Cytomegalic Inclusion Disease. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Cytomegalic Inclusion Disease, Cytomegalovirus Infection, COVID-19, and Severe Acute Respiratory Syndrome (SARS). Dr. Avery is board certified in American Board Of Internal Medicine.

Elite in Cytomegalic Inclusion Disease
Infectious Disease
Elite in Cytomegalic Inclusion Disease
Infectious Disease
Referral may be required

MacGregor Infection Medicine And Travel Program

3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Emily Blumberg is an Infectious Disease provider practicing medicine in Philadelphia, Pennsylvania. Dr. Blumberg is rated as an Elite provider by MediFind in the treatment of Cytomegalic Inclusion Disease. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Cytomegalovirus Infection, Cytomegalic Inclusion Disease, HIV/AIDS, Kidney Transplant, and Liver Transplant. Dr. Blumberg is board certified in Internal Medicine, 1984. Dr. Blumberg is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Cytomegalic Inclusion Disease
General Practice
Elite in Cytomegalic Inclusion Disease
General Practice

Office

1310 24th Ave S, 
Nashville, TN 
Languages Spoken:
English

James Goldenring is a primary care provider, practicing in General Practice in Nashville, Tennessee. Dr. Goldenring is rated as an Elite provider by MediFind in the treatment of Cytomegalic Inclusion Disease. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Microvillus Inclusion Disease, Cytomegalic Inclusion Disease, Stomach Cancer, and Menetrier Disease.

What are the latest Cytomegalic Inclusion Disease Clinical Trials?
Epidemiological Burden of and Risk Factors for Ganciclovir Resistant/Refractory Cytomegalovirus in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Patients: Multicentre Cohort Study

Summary: The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients...

Match to trials
Find the right clinical trials for you in under a minute
Get started
An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients

Summary: This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.